Key result
SAFE-SSPE trial tests whether clinical surveillance is non-inferior to rivaroxaban for VTE in low-risk SSPE.
Why the study?
The risk-benefit ratio of anticoagulation for isolated subsegmental pulmonary embolism is controversial and evidence from randomized controlled trials is lacking.
Does clinical surveillance without anticoagulation prevent symptomatic recurrent VTE non-inferiorly to rivaroxaban in low-risk patients with isolated subsegmental pulmonary embolism?
RCT
double-blind
randomised
Yes
Does clinical surveillance without anticoagulation prevent symptomatic recurrent VTE non-inferiorly to rivaroxaban in low-risk patients with isolated subsegmental pulmonary embolism?
This protocol outlines a trial to determine if clinical surveillance without anticoagulation is non-inferior to rivaroxaban for low-risk patients with isolated subsegmental pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Challenges routine anticoagulation in low-risk isolated SSPE; provides first RCT testing surveillance non-inferiority.
INTRODUCTION: The clinical significance of subsegmental pulmonary embolism (SSPE) is currently unclear. Although growing evidence from observational studies suggests that withholding anticoagulant treatment may be a safe option in selected patients with isolated SSPE, most patients with this condition receive anticoagulant treatment, which is associated with a 90-day risk of recurrent venous thromboembolism (VTE) of 0.8% and major bleeding of up to 5%. Given the ongoing controversy concerning the risk-benefit ratio of anticoagulation for isolated SSPE and the lack of evidence from randomised-controlled studies, the aim of this clinical trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation in low-risk patients with isolated SSPE. METHODS AND ANALYSIS: SAFE-SSPE (Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism, a multicentre randomised placebo-controlled non-inferiority trial) is an international, multicentre, placebo-controlled, double-blind, parallel-group non-inferiority trial conducted in Switzerland, the Netherlands and Canada. Low-risk patients with isolated SSPE are randomised to receive clinical surveillance with either placebo (no anticoagulation) or anticoagulant treatment with rivaroxaban. All patients undergo bilateral whole-leg compression ultrasonography to exclude concomitant deep vein thrombosis before enrolment. Patients are followed for 90 days. The primary outcome is symptomatic recurrent VTE (efficacy). The secondary outcomes include clinically significant bleeding and all-cause mortality (safety). The ancillary outcomes are health-related quality of life, functional status and medical resource utilisation. ETHICS AND DISSEMINATION: The local ethics committees in Switzerland have approved this protocol. Submission to the Ethical Committees in the Netherlands and Canada is underway. The results of this trial will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NCT04263038.
No takes yet. Share an insight, caveat, or question.
Baumgartner et al. (2020) conducted an RCT in isolated subsegmental pulmonary embolism. clinical surveillance with placebo vs. anticoagulant treatment with rivaroxaban was evaluated on symptomatic recurrent VTE. The SAFE-SSPE trial is a randomized, double-blind protocol designed to evaluate whether clinical surveillance is non-inferior to rivaroxaban for preventing recurrent VTE in low-risk isolated SSPE.
Synapse has enriched 10 related papers. Consider them for comparative context: